Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | Clonal evolution and resistance mechanisms to BCL-2 receptor inhibition

Mary Ann Anderson • 20 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia

Mary Ann Anderson, MBBS, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, discusses the development of resistance to BCL-2 receptor inhibition, and what it means for treatment strategies. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Mary Ann Anderson

Important factors to consider when selecting between venetoclax & BTK inhibitors for CLL 2:32
Important factors to consider when selecting between venetoclax & BTK inhibitors for CLL
Mary Ann Anderson • 8 Sep 2023
VENICE II trial: health-related QoL in patients with CLL treated with venetoclax 0:49
VENICE II trial: health-related QoL in patients with CLL treated with venetoclax
Mary Ann Anderson • 8 Sep 2023
Novel BCL-2 & BCL-2/BCLxL inhibitors emerging for the treatment of hematological malignancies 2:30
Novel BCL-2 & BCL-2/BCLxL inhibitors emerging for the treatment of hematological malignancies
Mary Ann Anderson • 8 Sep 2023
iwCLL 2019 – facilitating the development of novel agents and treatment outcomes 0:59
iwCLL 2019 – facilitating the development of novel agents and treatment outcomes
Mary Ann Anderson • 21 Sep 2019

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals